← FDA DRUG APPROVALS

FDA ANDA · ANDA072838

DILTIAZEM HYDROCHLORIDE

Sponsor: RISING

APPLICATION
ANDA072838
TYPE
ANDA
ORIGINAL APPROVAL
1992-11-05
LATEST ACTION
2020-05-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 30MG · TABLET · ORAL
DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 90MG · TABLET · ORAL
DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 60MG · TABLET · ORAL
DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 120MG · TABLET · ORAL

Approval history

2020-05-21Labeling · Supplement 24 · standardAP
2020-04-08Labeling · Supplement 23 · standardAP
2011-11-29Labeling · Supplement 19AP
2007-04-12Manufacturing (CMC) · Supplement 11AP
1999-07-12Manufacturing (CMC) · Supplement 7AP
1996-12-12Labeling · Supplement 6AP
1995-08-29Labeling · Supplement 4AP
1995-08-29Manufacturing (CMC) · Supplement 3AP
1995-07-13Labeling · Supplement 5AP
1993-12-13Labeling · Supplement 2AP
1992-11-05OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →